KRYS Up 53% In 2 Days, SLS To Report Phase 2 Data Next Week, OMED On Watch

(RTTNews) - The following are some of today's top gainers in the pharma/biotech sector.

1. Krystal Biotech Inc. (KRYS)

Gained 23.65% to close Tuesday's (Oct.16) trading at $24.73. This is the second straight day of double-digit gain for the stock.

On October 15, 2018, the Company announced positive interim results from its ongoing placebo-controlled phase I/II clinical trial of KB103 to treat dystrophic epidermolysis bullosa, or DEB.

DEB is an incurable, often fatal skin blistering condition caused by a lack of collagen protein in the skin. It is caused by mutations in the gene coding for type VII collagen, or COL7.

In the study, two adult DEB patients aged 35 and 28 years old have completed treatment with topical, gene therapy candidate KB103 to date. Results on the 2 patients met all primary efficacy and safety endpoints in topically administered KB103 wounds.

The phase I/II study is scheduled to be completed in the first half of 2019, and a pivotal phase III study is anticipated to commence in 2H 2019.

To know more about KRYS, please visit our "In the Spotlight" column.

2. Altimmune Inc. (ALT)

Gained 20.78% to close Tuesday's trading at $4.65.

News: No news

Pipeline:

Altimmune is a clinical-stage immunotherapeutics company having three clinical product candidates in its pipeline namely, NasoVAX, a phase II seasonal influenza vaccine candidate, HepTcell, a phase I immunotherapeutic candidate for the potential cure of chronic hepatitis B, SPARVAX-L, a phase II Anthrax vaccine, and NasoShield, a next generation Anthrax vaccine, under phase I study.

Recent events:

-- On October 11, the Company closed a registered direct offering of common units and pre-funded units for gross proceeds of approximately $25 million. -- On October 2, the Company closed a $12 million underwritten public offering. -- On September 26, the Company closed a $4.9 million registered direct offering.

3. SELLAS Life Sciences Group Inc. (SLS)

Gained 20% to close Tuesday's trading at $1.68.

Near-term Catalyst:

On October 22, 2018, the Company will be presenting interim (median follow-up of 18.8 months) and updated and final (median follow-up of 26.1 months) clinical data from its phase IIb trial of the combination of NeuVax and Herceptin to prevent breast cancer recurrence.

4. OncoMed Pharmaceuticals Inc. (OMED)

OncoMed is a clinical-stage biopharmaceutical company focused on developing novel anti-cancer therapeutics.

Gained 19.90% to close Tuesday's trading at $2.29.

News: No news

Pipeline:

-- Navicixizumab in combination with paclitaxel for the treatment of heavily pretreated, platinum-resistant ovarian cancer patients under phase Ib clinical trial. -- Etigilimab in combination with Opdivo in patients with advanced or metastatic solid tumors, under phase Ia/b study. -- OMP-336B11, under phase Ia study, in patients with advanced or metastatic solid tumors.

Near-term Catalyst:

Interim results of the ongoing phase Ib study of Navicixizumab in combination with paclitaxel in patients with platinum-resistant ovarian cancer are scheduled to be presented on October 20, 2018.

5. Aileron Therapeutics Inc. (ALRN)

Gained 18.64% to close Tuesday's trading at $2.80.

News: No news

Pipeline:

The Company's lead product candidate is ALRN-6924.

Multiple clinical studies of ALRN-6924 are underway, including a Phase 1 All-comers trial in advanced solid tumors or lymphomas, a Phase 2a trial in peripheral T-cell lymphoma (PTCL), a Phase 1 trial in acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS) as a monotherapy, and a Phase 1b trial in AML/MDS in combination with cytosine arabinoside (Ara-C).

Near-term Catalysts:

-- Additional interim data from the Phase 2a trial of ALRN-6924 for the treatment of patients with peripheral T-cell lymphoma are expected to be reported this quarter. (Q4). -- Interim data from Phase 1 and 1b open-label, multi-center clinical trials of ALRN-6924 as a monotherapy and in combination with cytosine arabinoside (Ara-C) for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are also expected this quarter (Q4).

6. Autolus Therapeutics plc (AUTL)

Gained 15.95% to close Tuesday's trading at $28.86.

Autolus is a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies.

News: No news

Recent event:

On June 22, 2018, the Company went public on the Nasdaq Global Select Market, offering its American Depositary Shares at a price of $17.00 per ADS.

Pipeline:

-- AUTO1, under a phase I trial in patients with pediatric relapsed or refractory acute B lymphocytic leukemia, or pediatric ALL, and a phase I clinical trial in adult patients with ALL. -- AUTO2, under a phase I/II clinical trial in relapsed or refractory multiple myeloma. -- AUTO3, under phase I/II clinical trials in diffuse large B-cell lymphoma, and pediatric ALL.

Related Reading

Do You Have These Pharma Stocks In Your Portfolio?